Form 4: Allogene Therapeutics Director Owen N. Witte Acquires Stock Options
SEC Form 4 Filing
Director Owen N. Witte acquired stock options for Allogene Therapeutics, Inc. on June 5, 2024.
Summary
- On June 5, 2024, Owen N. Witte, a director of Allogene Therapeutics, Inc., acquired stock options to purchase 191,082 shares of common stock.
- The exercise price of these options is $2.44.
- The options vest in 12 equal monthly installments and expire on June 5, 2034.
- Following the transaction, Witte directly owns 191,082 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a stock option grant to a director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of earliest transaction: Acquisition of stock options. |
| 06/05/2024 | Date exercisable for stock options. |
| 06/05/2034 | Expiration date for stock options. |
| 06/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.